We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

138 hedge funds and large institutions have $85.3M invested in Nektar Therapeutics in 2023 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 32 increasing their positions, 47 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% more capital invested

Capital invested by funds: $79.3M → $85.3M (+$5.99M)

0.17% more ownership

Funds ownership: 4.86% → 5.02% (+0.17%)

5% less funds holding

Funds holding: 146 → 138 (-8)

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

32% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 47

52% less call options, than puts

Call options by funds: $23K | Put options by funds: $48K

Holders
138
Holders Change
-8
Holders Change %
-5.48%
% of All Funds
2.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
32
Reduced
47
Closed
23
Calls
$23K
Puts
$48K
Net Calls
-$25K
Net Calls Change
-$300K

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$12M
2
TCM
Tang Capital Management
California
+$2.44M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.07M
4
Marshall Wace
Marshall Wace
United Kingdom
+$1.88M
5
LCM
Lynx1 Capital Management
Puerto Rico
+$1.13M

Top Sellers

1
SCM
Sio Capital Management
New York
-$4.02M
2
Invesco
Invesco
Georgia
-$3.32M
3
MAM
Monaco Asset Management
Monaco
-$2.86M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.62M
5
Millennium Management
Millennium Management
New York
-$2.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$709K -$2.11M -218,684 -73%
Charles Schwab
27
Charles Schwab
California
$640K +$47.5K +4,934 +7%
Goldman Sachs
28
Goldman Sachs
New York
$611K -$177K -18,394 -21%
Morgan Stanley
29
Morgan Stanley
New York
$506K -$464K -48,233 -46%
CM
30
CM Management
Florida
$476K +$32.1K +3,333 +7%
AI
31
Acuitas Investments
Washington
$430K -$29 -3 -0%
State Street
32
State Street
Massachusetts
$427K -$6.3K -654 -1%
Dimensional Fund Advisors
33
Dimensional Fund Advisors
Texas
$350K -$142K -14,738 -27%
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$293K -$91.6K -9,513 -22%
Ameriprise
35
Ameriprise
Minnesota
$291K -$1.28K -133 -0.4%
Northern Trust
36
Northern Trust
Illinois
$214K -$3.8K -395 -2%
Invesco
37
Invesco
Georgia
$214K -$3.32M -345,073 -94%
Ohio Public Employees Retirement System (OPERS)
38
Ohio Public Employees Retirement System (OPERS)
Ohio
$185K -$645 -67 -0.3%
DZ Bank
39
DZ Bank
Germany
$172K – – –
Norges Bank
40
Norges Bank
Norway
$156K – – –
Macquarie Group
41
Macquarie Group
Australia
$153K – – –
Bank of America
42
Bank of America
North Carolina
$147K +$43.3K +4,496 +38%
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$146K +$53.5K +5,560 +51%
Barclays
44
Barclays
United Kingdom
$137K +$111K +11,501 +301%
AG
45
Algert Global
California
$108K – – –
MSAM
46
Moloney Securities Asset Management
Missouri
$107K -$112K -11,667 -49%
Russell Investments Group
47
Russell Investments Group
United Kingdom
$94.5K -$1.11K -115 -1%
MAM
48
Marquette Asset Management
Minnesota
$88.4K – – –
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
$83.6K -$157K -16,274 -63%
Cambridge Investment Research Advisors
50
Cambridge Investment Research Advisors
Iowa
$80K -$1.45K -151 -2%
1
2
3 4 5

NKTR Hedge Fund Activity: Q3 2023 in Review

138 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2023, worth a combined $85.3M — up 7.6% from $79.3M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of NKTR and 16 opened new positions — a net loss of 7 holders — while 47 trimmed existing stakes and 32 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $12M. The largest seller was Sio Capital Management, exiting entirely with an estimated $4.02M sold.

  • 138 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2023, down from 146 in Q2 2023.
  • Funds reported $85.3M of Nektar Therapeutics stock for Q3 2023, up 7.6% quarter-over-quarter.
  • 16 funds opened new Nektar Therapeutics positions in Q3 2023 and 23 closed out, a net change of -7 holders.
  • The largest Nektar Therapeutics buyer in Q3 2023 was RA Capital Management, an estimated $12M added.
  • The largest Nektar Therapeutics seller in Q3 2023 was Sio Capital Management, an estimated $4.02M sold.

Based on aggregated 13F filings for Q3 2023.